Investment Management Corp of Ontario Has $2.41 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Investment Management Corp of Ontario raised its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 102.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,242 shares of the medical research company's stock after buying an additional 6,193 shares during the period. Investment Management Corp of Ontario's holdings in IQVIA were worth $2,406,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Synergy Asset Management LLC bought a new position in shares of IQVIA in the fourth quarter worth about $33,000. GKV Capital Management Co. Inc. bought a new position in shares of IQVIA in the fourth quarter worth about $39,000. Lee Danner & Bass Inc. bought a new position in shares of IQVIA in the fourth quarter worth about $44,000. Zions Bancorporation N.A. grew its position in IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock worth $47,000 after buying an additional 85 shares in the last quarter. Finally, SBI Securities Co. Ltd. acquired a new stake in IQVIA during the fourth quarter worth about $60,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Trading Down 0.9%

NYSE:IQV traded down $1.31 during trading hours on Thursday, hitting $140.51. 2,595,876 shares of the stock were exchanged, compared to its average volume of 1,504,221. The company's 50 day moving average is $161.62 and its two-hundred day moving average is $187.11. IQVIA Holdings Inc. has a twelve month low of $135.97 and a twelve month high of $252.88. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The company has a market capitalization of $24.31 billion, a P/E ratio of 18.73, a price-to-earnings-growth ratio of 1.99 and a beta of 1.34.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.63 by $0.07. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The firm had revenue of $3.83 billion for the quarter, compared to the consensus estimate of $3.77 billion. During the same quarter in the prior year, the business earned $2.54 EPS. The business's revenue for the quarter was up 2.5% compared to the same quarter last year. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

IQV has been the topic of a number of recent research reports. StockNews.com downgraded IQVIA from a "buy" rating to a "hold" rating in a research report on Wednesday, March 12th. Robert W. Baird decreased their target price on IQVIA from $195.00 to $161.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Royal Bank of Canada reissued an "outperform" rating and set a $270.00 target price on shares of IQVIA in a research report on Monday, February 10th. Barclays decreased their price objective on IQVIA from $170.00 to $165.00 and set an "equal weight" rating on the stock in a report on Wednesday, May 7th. Finally, BTIG Research downgraded IQVIA from a "buy" rating to a "neutral" rating in a report on Monday, February 3rd. Eight analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $230.76.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.